John Maraganore shares his take on biotech in 2025 and discusses the science behind his recently launched RNAi company, City Therapeutics

News

Feb 11

Written By Rachel Swansburg

News

Rachel Swansburg

City Therapeutics Expands Executive Team and Board of Directors

Bausch + Lomb pens $485M-plus biobucks pact with City Tx for RNAi eye disease work